Por favor, use este identificador para citar o enlazar este ítem:
DOI:10.14670/HH-11-830
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Corominas Faja, Bruna | - |
dc.contributor.author | Vellon, Luciano | - |
dc.contributor.author | Cuyàs, Elisabet | - |
dc.contributor.author | Buxó, Maria | - |
dc.contributor.author | Martin Castillo, Begoña | - |
dc.contributor.author | Serra, Dolors | - |
dc.contributor.author | García, Jordi | - |
dc.contributor.author | Menendez, Javier A. | - |
dc.contributor.author | Lupu, Ruth | - |
dc.date.accessioned | 2022-02-24T09:34:14Z | - |
dc.date.available | 2022-02-24T09:34:14Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Histology and Histopathology, Vol.32, nº7, (2017) | es |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.uri | http://hdl.handle.net/10201/117365 | - |
dc.description.abstract | Fatty acid synthase (FASN) is a key lipogenic enzyme for de novo fatty acid biosynthesis and a druggable metabolic oncoprotein that is activated in most human cancers. We evaluated whether the HER2- driven lipogenic phenotype might represent a biomarker for sensitivity to pharmacological FASN blockade. A majority of clinically HER2-positive tumors were scored as FASN overexpressors in a series of almost 200 patients with invasive breast carcinoma. Reclassification of HER2-positive breast tumors based on FASN gene expression predicted a significantly inferior relapse-free and distant metastasis-free survival in HER2+/FASN+ patients. Notably, non-tumorigenic MCF10A breast epithelial cells engineered to overexpress HER2 upregulated FASN gene expression, and the FASN inhibitor C75 abolished HER2-induced anchorage-independent growth and survival. Furthermore, in the presence of high concentrations of C75, HER2-negative MCF-7 breast cancer cells overexpressing HER2 (MCF-7/HER2) had significantly higher levels of apoptosis than HER2-negative cells. Finally, C75 at non-cytotoxic concentrations significantly reduced the capacity of MCF-7/HER2 cells to form mammospheres, an in vitro indicator of cancer stem-like cells. Collectively, our findings strongly suggest that the HER2-FASN lipogenic axis delineates a group of breast cancer patients that might benefit from treatment with therapeutic regimens containing FASN inhibitors. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia. Departamento de Biología Celular e Histología | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Fatty acid syntase | es |
dc.subject | Breast cancer | es |
dc.subject | C75 | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es |
dc.title | Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | DOI:10.14670/HH-11-830 | - |
Aparece en las colecciones: | Vol.32, nº7 (2017) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Corominas-Faja-32-687-698-2017.pdf | 7,08 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons